^
8ms
Enrollment closed • Enrollment change • Metastases
|
cyclophosphamide • fludarabine IV • mesna • OBX-115 • acetazolamide
9ms
Safety and Efficacy of OBX-115 in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=52, Recruiting, Obsidian Therapeutics, Inc. | N=32 --> 52
Enrollment change • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
|
BRAF mutation • BRAF V600
|
cyclophosphamide • OBX-115
1year
Safety and Efficacy of OBX-115 in Advanced/Metastatic Melanoma Resistant to Immune Checkpoint Inhibitors (clinicaltrials.gov)
P1/2, N=32, Recruiting, Obsidian Therapeutics, Inc. | Active, not recruiting --> Recruiting
Enrollment open • Checkpoint inhibition • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
|
BRAF mutation • BRAF V600
|
cyclophosphamide • OBX-115
1year
New P1/2 trial • Checkpoint inhibition • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
|
BRAF mutation • BRAF V600
|
cyclophosphamide • OBX-115
over1year
IL15-engineered tumor infiltrating lymphocytes (cytoTIL15TM) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2 (AACR 2023)
We previously showed that melanoma TILs engineered to express membrane-bound IL15 (mbIL15) under the control of the ligand acetazolamide (ACZ) can achieve IL2-independent expansion during manufacturing, antigen-independent persistence in vitro and anti-tumor efficacy in vivo. Unlike unengineered TILs, cytoTIL15 cells + ACZ persisted in an antigen-free setting without IL2, were cytotoxic to autologous PDc and released IFNγ in response to autologous PDx tumor digest. Taken together, these data show that IL2-independent, fully functional cytoTIL15 cells can successfully be generated from tumors such as NSCLC, HNSCC & TNBC, which afflict large numbers of patients.
Late-breaking abstract • Tumor-infiltrating lymphocyte • IO biomarker • Tumor cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
|
CD8 positive
|
OBX-115 • acetazolamide
2years
Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15 therapy) in an allogeneic melanoma PDX model (SITC 2022)
Methods cytoTIL15® therapy contains TILs engineered with mbIL15 under the control of a carbonic-anhydrase-2 drug responsive domain, regulated by the ligand acetazolamide (ACZ). Interestingly, the subpopulation of cytoTIL15® cells reactive to tumor-associated antigen MART-1 displayed increased expression of TCF-1, which in melanoma patients has been associated with responses to immune checkpoint blockade, in addition to progression-free and overall survival. Ethics Approval All animal studies were IACUC approved.
Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • IL15 (Interleukin 15) • TRB (T Cell Receptor Beta Locus)
|
OBX-115 • acetazolamide
2years
Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments (SITC 2022)
Cytokines modified with our carbonic anhydrase 2 (CA2)-based cytoDRiVE® drug responsive domain (DRD) were evaluated for control of protein levels with the CA2 ligand, acetazolamide (ACZ). Conclusions While IL-15 drives expansion and persistence of cytoTIL15 TM cells without IL-2, adding pleotropic and highly immune-stimulatory members of the IFN, IL-1 or TNF families may provide enhanced efficacy for patients with solid tumors marked by an immunosuppressive TME. Ethics Approval All animal studies were IACUC approved
Clinical • Tumor-Infiltrating Lymphocyte
|
IL18 (Interleukin 18) • IFNA1 (Interferon Alpha 1) • IL15 (Interleukin 15) • PMEL (Premelanosome Protein)
|
OBX-115 • acetazolamide
over2years
Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15TM) eradicate tumors in a melanoma PDX model through recognition of shared tumor antigens (AACR 2022)
To this end, we genetically engineered TIL to express membrane-bound IL-15 (mbIL15) under the control of Obsidian’s cytoDRIVE® technology (cytoTIL15TM), which allows regulation of protein expression via a drug-responsive domain upon acetazolamide (ACZ) administration. Moreover, enhanced cytoTIL15 cell infiltration and anti-tumor activity was associated with increases in pro-inflammatory cytokines (e.g., IFNγ). Taken together, these data clearly demonstrate the superiority of cytoTIL15 cells over uTIL for controlling or eradicating melanoma tumor outgrowth and the utility of an allogeneic PDX model for comparative evaluation of tumor-antigen specific TIL reactivity.
Late-breaking abstract • Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • MLANA (Melan-A) • IL15 (Interleukin 15)
|
HLA-A*02
|
OBX-115 • acetazolamide
3years
Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo (SITC 2021)
cytoTIL15 contains TILs engineered with mbIL15 under the control of a carbonic-anhydrase-2 DRD, controlled by the ligand acetazolamide (ACZ). Importantly, cytoTIL15 achieved significant tumor control in a human PDX model (figure 1D), which correlated with increased TIL accumulation in secondary lymphoid organs. Conclusions Taken together, the superior persistence and potency of cytoTIL15 in the complete absence of IL-2 highlights the clinical potential of cytoTIL15 as a novel TIL product with enhanced safety and efficacy for patients with melanomas, and other solid tumors.
Preclinical • Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
OBX-115 • acetazolamide
over3years
[VIRTUAL] cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility (ESMO 2021)
Unlike IL2, IL15 does not increase immunosuppressive regulatory T-cells and drives T-cell differentiation towards a stem-cell memory phenotype associated with long-term persistence. cytoTIL15 uses Obsidian’s cytoDRiVE® platform, which consists of a carbonic anhydrase 2 (CA2) derived drug responsive domain that enables regulated expression of mbIL15 under control of acetazolamide (ACZ), an FDA-approved orally bioavailable small molecule ligand. cytoTIL15 is a more potent and persistent TIL product that does not require infusion of IL2, thereby enhancing the safety and durable efficacy of TIL therapy for patients with metastatic melanoma and other solid tumor malignancies.
Clinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
|
OBX-115 • acetazolamide